Major US Formulary Change Triggers, but Does Not Sustain, Increases in Biosimilar Adalimumab Prescribing
Authors' conclusion
Although biosimilar adalimumab prescriptions rose sharply after a major national formulary change, the increase was not sustained.
Study context
- Population
- Patients in US community rheumatology practices in the Rheumatology Informatics System for Effectiveness registry, January 2023 to September 2024
- Participants
- 22,079 patients
- Exposure
- Before vs after the 2024 CVS Caremark formulary change preferring adalimumab-adaz over originator
- Outcome
- Monthly proportion of patients prescribed adalimumab-adaz or other adalimumab biosimilars
Methodological detailsregistry-based (RISE), stratified by payor and among new users
- Registry-based (RISE)
- Stratified by payor and among new users
Main finding
As reported in the abstract
Biosimilar adalimumab prescribing after the formulary change
Commercially insured: adalimumab-adaz prescriptions dropped in the next month
12.3%
Observational data: associations, not effects.
Further findings
New users: biosimilar adalimumab prescribing
- Decrease in adalimumab-adaz prescriptions in the first month after the change
- nearly 14%
- Other biosimilar prescriptions increased per month throughout the period
- 0.6%
- Adalimumab-adaz prescriptions increased from 0% to 24%
Original publication
Major US Formulary Change Triggers, but Does Not Sustain, Increases in Biosimilar Adalimumab Prescribing. Arthritis Care Res (Hoboken). Published 6 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →